
Industrial evolution: Indian pharma needs a major R&D-oriented reset
It is time Indian pharma moved up the value chain from producing cheap generics—drugs whose patents have expired and can be made by companies other than their originators and licensees—and started creating new lines of therapy. Also Read: Glenmark unit …